Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 + finotonlimab neoadjuvant phase II trial in locally advanced head and neck squamous cell carcinoma
ChiCTR2600133273Phase 2Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of becotatug vedotin and finotonlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Foshan First People's Hospital. Primary endpoint: Objective Response Rate. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinfinotonlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600133273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133273.